Belgian Construction Stock News

On 15 December 2025, argenx SE said it would discontinue its Phase 3 UplighTED trials of subcutaneous efgartigimod in adults with moderate to severe thyroid eye disease after an Independent Data Monitoring Committee found the study was unlikely to meet its efficacy goals, despite a favorable safety profile and no new safety signals. The company now plans a full analysis of the interim data to understand why the drug underperformed on proptosis response and other endpoints, and to extract...

Earlier in December 2025, UCB reported positive Phase 3 data at the American Epilepsy Society meeting showing adjunctive fenfluramine significantly reduced seizure frequency in children and adults with CDKL5 deficiency disorder, meeting its primary and key secondary endpoints over 14 weeks. This outcome strengthens fenfluramine’s clinical profile in a rare, severe epilepsy where no approved treatments currently exist, potentially broadening UCB’s neurology footprint if regulators eventually...

The Crescent NV ( EBR:OPTI ) share price has softened a substantial 29% over the previous 30 days, handing back much of...

SCR-Sibelco (ENXTBR:094426466) has quietly outperformed over the past year, even as returns were mixed in the past 3 years and 5 years. This makes the current share price worth a closer look. See our latest analysis for SCR-Sibelco. With the share price now at $4,700 and a modest 1 month share price return of 1.73 percent, the real story is the 1 year total shareholder return of 9.3 percent, which suggests momentum is quietly rebuilding after a tougher multi year patch. If SCR-Sibelco’s...

Ontex Group has announced that Europe Division President Laurent Nielly will succeed Gustavo Calvo Paz as CEO after the May 5, 2026 shareholders’ meeting, while also cutting its 2025 revenue outlook and warning of a high single digit like-for-like revenue drop in the fourth quarter versus last year. At the same time, Ontex is tripling baby pants production capacity in North America to support retailer-brand growth in a segment where U.S. consumers are increasingly opting for affordable,...

As European markets navigate mixed performances, with Germany's DAX showing gains while the UK and France face slight declines, investors are closely monitoring economic indicators and central bank policies for potential opportunities. In this dynamic environment, identifying promising stocks often involves looking at companies that can thrive amidst economic resilience and shifting interest rate expectations.

With its stock down 11% over the past three months, it is easy to disregard Melexis (EBR:MELE). However, the company's...

argenx (ENXTBR:ARGX) heads into the Antibody Engineering and Therapeutics conference in San Diego, with investors watching closely for fresh signals on its antibody pipeline and what that might mean for the stock. See our latest analysis for argenx. The conference buzz comes after a strong run for argenx, with the share price now at $753.2 and a roughly 18% 3 month share price return contributing to a 106% three year total shareholder return. This suggests momentum is still very much on its...

Key Insights The projected fair value for Campine is €183 based on 2 Stage Free Cash Flow to Equity Campine's €180...

Key Insights The projected fair value for Lotus Bakeries is €6,590 based on 2 Stage Free Cash Flow to Equity Lotus...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Wondering if ageas is still good value after a strong run, or if most of the upside is already baked in? You are not alone, and this article will help you size that up calmly. The stock is up 21.6% year to date and 27.3% over the last 12 months, even after a modest 1.0% pullback over the past month. This suggests the market has been reassessing its prospects over time. Recent news flow around European insurers has focused on tighter capital rules, shifts in interest rate expectations and how...

DEME Group has recently secured three contracts to install monopile foundations, inter-array cables and an export cable for the BC-Wind offshore wind farm in Poland, reinforcing its role in the country’s renewable energy rollout. These wins further deepen DEME’s exposure to offshore wind infrastructure, expanding its project pipeline in a market focused on accelerating its energy transition. We’ll now examine how securing BC-Wind’s foundation and cable installation work could influence...

Anheuser-Busch InBev (ENXTBR:ABI) has quietly outperformed the broader market over the past 3 months. That kind of steady move usually signals that investors are reassessing its earnings power and valuation. See our latest analysis for Anheuser-Busch InBev. Looking beyond the recent 3 month share price return of 8.24%, ABI’s 1 year total shareholder return of 7.70% suggests steady, if not spectacular, progress as investors cautiously reprice its earnings momentum and leverage risks. If ABI’s...

You may think that with a price-to-sales (or "P/S") ratio of 0.2x Ontex Group NV ( EBR:ONTEX ) is a stock worth...

It hasn't been the best quarter for Colruyt Group N.V. ( EBR:COLR ) shareholders, since the share price has fallen 12...

You may think that with a price-to-sales (or "P/S") ratio of 1.3x Compagnie du Bois Sauvage S.A. ( EBR:COMB ) is a...

Vastned (ENXTBR:VASTB) has put solid numbers on the table for Q3 2025, with recent quarterly revenue sitting at about €16.9 million and EPS at roughly €0.81, backed by trailing twelve month revenue of €42.9 million and EPS of €2.65. The company has seen revenue move from €4.9 million in Q2 2024 to €16.9 million in Q2 2025, while EPS shifted from €0.87 to €0.81 over the same quarters. This sets the stage for investors to focus on how much of the headline growth is sustainable versus one off...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...

Wondering if Anheuser-Busch InBev is quietly trading below what it is really worth, or if the market already sees the upside you are hoping for? Despite a modest 6.6% gain year to date and a 4.5% return over the last year, the stock has slipped recently, down 2.0% over the past week and 4.6% across the last month. These moves can influence how investors view both its growth potential and its risk profile. Recent headlines have focused on the company’s efforts to rebuild brand momentum in key...

Solvay (ENXTBR:SOLB) has drifted lower this year, even as its long term track record and steady cash generation remain intact. This may create an interesting entry point for investors who can tolerate near term volatility. See our latest analysis for Solvay. Over the past year, Solvay has seen its share price drift lower, with a year to date share price return of minus 12.08 percent. Even so, its five year total shareholder return of 70.32 percent still points to a solid long term wealth...

Cmb.Tech NV has reported earnings for the nine months ended 30 September 2025, with sales rising to US$1,077.1 million but revenue and net income falling to US$1,248.43 million and US$71.64 million respectively compared with the same period a year earlier. Alongside weaker profitability and a sharp drop in earnings per share from continuing operations, CMB.TECH still plans to propose an interim dividend of US$0.05 per share, highlighting a continued commitment to shareholder payouts. With...

Cmb.Tech (ENXTBR:CMBT) just released a mixed nine month update, reporting higher sales but sharply lower net income, and paired it with a small interim dividend proposal that changes the near term income story. See our latest analysis for Cmb.Tech. The mixed earnings and fresh interim dividend proposal come after a volatile run, with a strong 30 day share price return of 17.36 percent but a softer 1 year total shareholder return of 8.23 percent in the red. This suggests momentum is improving...